Pawarode Attaphol, Shukla Suneet, Minderman Hans, Fricke Stacy M, Pinder Elaine M, O'Loughlin Kieran L, Ambudkar Suresh V, Baer Maria R
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Cancer Chemother Pharmacol. 2007 Jul;60(2):179-88. doi: 10.1007/s00280-006-0357-8. Epub 2006 Oct 10.
We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).
Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus. Interaction of BCRP with these compounds was studied by photolabeling and ATPase assays. Nuclear-cytoplasmic distribution of doxorubicin was studied by confocal microscopy in cells overexpressing LRP.
CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clinically achievable concentration of 2.5 microM. Tacrolimus enhanced cellular drug uptake at 1 microM, but not at 0.08 microM, its clinically achievable concentration, and did not enhance nuclear drug uptake. Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM. BCRP modulation by all three immunosuppressive agents was associated with competitive binding to the drug transport sites.
CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.
我们试图确定免疫抑制剂环孢素A(CsA)、他克莫司和西罗莫司对ATP结合盒蛋白、P-糖蛋白(Pgp;ABCB1)、多药耐药蛋白-1(MRP-1;ABCC1)、乳腺癌耐药蛋白(BCRP;ABCG2)以及主要穹窿蛋白肺耐药蛋白(LRP)介导的药物转运的影响。
米托蒽醌是一种Pgp、MRP-1和BCRP的底物,在过表达这些蛋白的细胞中,分别在加入和不加入CsA、他克莫司或西罗莫司孵育后,通过流式细胞术测定其细胞内含量。通过光标记和ATP酶分析研究BCRP与这些化合物的相互作用。在过表达LRP的细胞中,通过共聚焦显微镜研究阿霉素的核质分布。
在临床可达到的浓度2.5微摩尔/升时,CsA增加了过表达Pgp、MRP-1或BCRP的细胞中的药物摄取,并增加了过表达LRP的细胞中的核药物摄取。他克莫司在1微摩尔/升时增强了细胞药物摄取,但在其临床可达到的浓度0.08微摩尔/升时没有增强,且未增强核药物摄取。西罗莫司在2.5微摩尔/升时对过表达Pgp、MRP-1和BCRP的细胞增强了细胞药物摄取,效果最佳,但如果细胞在药物暴露前预先孵育至少30分钟,则在其临床可达到的浓度0.25微摩尔/升时也有效,并且在0.25微摩尔/升时也增强了核药物摄取。所有三种免疫抑制剂对BCRP的调节都与竞争性结合药物转运位点有关。
CsA、他克莫司和西罗莫司在不同于免疫抑制浓度和最大耐受浓度的浓度下调节Pgp、MRP-1和BCRP介导的药物转运,CsA和西罗莫司调节LRP介导的药物转运。